Department of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang 443002, Hubei, PR China; The Institute of Infection and Inflammation, China Three Gorges University, Yichang 443002, Hubei, PR China; Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-X Institute, Huazhong University of Science and Technology, Wuhan 430074, Hubei, PR China.
Department of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang 443002, Hubei, PR China; The Institute of Infection and Inflammation, China Three Gorges University, Yichang 443002, Hubei, PR China.
Biochim Biophys Acta Mol Basis Dis. 2021 Jul 1;1867(7):166130. doi: 10.1016/j.bbadis.2021.166130. Epub 2021 Mar 18.
A high level of low-density lipoprotein cholesterol (LDL) is one of the most important risk factors for coronary artery disease (CAD), the leading cause of death worldwide. However, a low concentration of LDL may be protective. Genome-wide association studies revealed that variation in ADTRP gene increased the risk of CAD. In this study, we found that a low concentration of oxidized-LDL induced the expression of ADTRP. Further analyses showed that knockdown of the expression of LDL receptor genes LDLR, CD36, or LOX-1 significantly downregulated ADTRP expression, whereas overexpression of LDLR/CD36/LOX-1 markedly increased ADTRP expression through the NF-κB pathway. Like ADTRP, LDLR, CD36 and LOX-1 were all involved in endothelial cell (EC) functions relevant to the initiation of atherosclerosis. Downregulation of LDLR/CD36/LOX-1 promoted monocyte adhesion to ECs and transendothelial migration of monocytes by increasing expression of ICAM-1, VCAM-1, E-selectin and P-selectin, decreased EC proliferation and migration, and increased EC apoptosis, thereby promoting the initiation of atherosclerosis. Opposite effects were observed with the overexpression of ADTRP and LDLR/CD36/LOX-1 in ECs. Interestingly, through the NF-κB and AKT pathways, overexpression of ADTRP significantly upregulated the expression of LDLR, CD36, and LOX-1, and knockdown of ADTRP expression significantly downregulated the expression of LDLR, CD36, and LOX-1. These data suggest that ADTRP and LDL receptors LDLR/CD36/LOX-1 positively regulate each other, and form a positive regulatory loop that regulates endothelial cell functions, thereby providing a potential protective mechanism against atherosclerosis. Our findings provide a new molecular mechanism by which deregulation of ADTRP and LDLR/CD36/LOX-1 promote the development of atherosclerosis and CAD.
高水平的低密度脂蛋白胆固醇(LDL)是导致冠状动脉疾病(CAD)的最重要危险因素之一,CAD 是全球范围内的主要死亡原因。然而,低浓度的 LDL 可能具有保护作用。全基因组关联研究表明,ADTRP 基因的变异增加了 CAD 的风险。在这项研究中,我们发现氧化 LDL 可诱导 ADTRP 的表达。进一步分析表明,敲低 LDLR、CD36 或 LOX-1 基因的表达可显著下调 ADTRP 的表达,而过表达 LDLR/CD36/LOX-1 则通过 NF-κB 途径显著增加 ADTRP 的表达。与 ADTRP 一样,LDLR、CD36 和 LOX-1 均参与与动脉粥样硬化起始相关的内皮细胞(EC)功能。LDLR/CD36/LOX-1 下调可通过增加 ICAM-1、VCAM-1、E-选择素和 P-选择素的表达,促进单核细胞与 EC 的黏附以及单核细胞的跨内皮迁移,从而促进动脉粥样硬化的起始。相反,ADTRP 和 LDLR/CD36/LOX-1 在 EC 中的过表达则观察到相反的作用。有趣的是,通过 NF-κB 和 AKT 途径,ADTRP 的过表达可显著上调 LDLR、CD36 和 LOX-1 的表达,而 ADTRP 表达的下调则显著下调 LDLR、CD36 和 LOX-1 的表达。这些数据表明,ADTRP 和 LDL 受体 LDLR/CD36/LOX-1 相互正向调节,形成一个正反馈调节环路,调节内皮细胞功能,从而为对抗动脉粥样硬化提供了一种潜在的保护机制。我们的研究结果提供了一个新的分子机制,即 ADTRP 和 LDLR/CD36/LOX-1 的失调促进了动脉粥样硬化和 CAD 的发展。